Tempus AI, Inc. announced on Thursday a strategic partnership with the Keck School of Medicine of USC and Keck Medicine of USC, marking a significant expansion of its molecular testing and artificial intelligence capabilities into a major Southern California health system. The agreement will bring Tempus's molecular diagnostics, AI-driven care-gap analysis, and clinical trial matching tools to USC Norris Comprehensive Cancer Center, Keck Hospital of USC, USC Verdugo Hills Hospital, and other affiliated facilities.
Deal Details and Scope
The partnership targets over 1.5 million annual patient visits, with a focus on leveraging broad clinical datasets to personalize care through precision medicine. This approach aligns treatment with a patient's tumor profile, genetic makeup, and medical history. The collaboration includes four core initiatives: clinical testing, automated patient-to-trial matching via Tempus's TIME Trial Program, AI-driven care-gap pathways to identify missed or overdue guideline-based care steps, and collaborative research for developing new diagnostics and therapeutics.
Market Reaction
Despite the strategic significance, Tempus AI shares closed 7.3% lower at $51.44 on Nasdaq, with a slight after-hours uptick to $51.68 as of 5 p.m. EDT, according to MarketScreener data. The decline reflects investor caution ahead of the company's first-quarter earnings report scheduled for May 5, where founder and CEO Eric Lefkofsky and CFO Jim Rogers will discuss results.
Financial Context and Growth Trajectory
Tempus, coming off a year of rapid expansion, reported $1.27 billion in revenue for 2025, an 83.4% increase year-over-year. Diagnostics generated $955.4 million, while data and applications contributed $316.4 million. However, the company ended the year with a net loss of $245.0 million. For 2026, Tempus projects revenue of approximately $1.59 billion and adjusted EBITDA near $65 million, underscoring the need for partnerships like USC to drive usage, contract growth, and data scale.
Competitive Landscape
The agreement intensifies Tempus's competition in the cancer genomics market against players such as Roche's Foundation Medicine and Guardant Health. Guardant Health recently filed a DNA-testing patent lawsuit against Tempus, highlighting the fierce rivalry in blood-based cancer testing. The USC deal positions Tempus to deepen its integration into hospital workflows, moving beyond lab services or data licensing.
Leadership Perspectives
Vasiliki Anest, chief innovation officer at Keck School of Medicine, noted that the collaboration aligns research, clinical care, and innovation priorities. Steven Shapiro, USC's senior vice president for health affairs, emphasized the potential to guide patients toward the most appropriate clinical trials and treatments. Ezra Cohen, Tempus's chief medical officer for oncology, described the opportunity to create an integrated ecosystem linking Tempus's AI platform with USC's clinical and research operations.
Outlook and Risks
While the partnership is a milestone, financial details remain undisclosed, and timelines for clinical adoption, reimbursement, and revenue generation from trial matching are unclear. Tempus described anticipated benefits as forward-looking, citing risks such as customer retention, rising costs, competition, and evolving AI regulations. Investors will closely watch the May 5 earnings report for evidence that such partnerships translate into tangible financial results.
